In this randomized controlled trial, nicotinamide riboside reduced levels of the inflammatory marker interleukin 8 in the airways of participants with chronic obstructive pulmonary disease.
This Study Summary was published on January 3, 2025.
In this randomized controlled trial, nicotinamide riboside reduced levels of the inflammatory marker interleukin 8 in the airways of participants with chronic obstructive pulmonary disease.
This Study Summary was published on January 3, 2025.
